

Table 1 Short-term surgical outcomes in older patients
Ordered by age, time period

1 st author, year (reference)	Study characteristics				N			MV Adj	30-day mortality %			Any morbidity %			Gr ≥3 morbidity %		
	Years	Age	Stage ^a	Population, comments	W	Seg	Lobe		W	Seg	Lobe	W	Seg	Lobe	W	Seg	Lobe
Zhang 2019 (11)	2014-17	≥65	cl-IIA	China x10	309	106	1,164	-	0 ^b	0 ^b	0.4 ^b	[2] ^c	[9] ^c	[7] ^c	-	-	-
Shirvani 2014 (12)	2003-9	≥65	cl-IIA	SEER-Medicare	1,496 ^d	-	7,215	-	3.7 ^{b,d}	-	4 ^b	-	-	-	-	-	-
Billmeier 2011 (13)	2003-05	≥65	I-III ^e	CanCORS	155 ^f	-	524	Y	6.5 ^f	-	2.9	18	-	18 ^f	-	-	-
Altorki 2018 (14)	2007-17	≥70	clA1,2	Prospective, 80% VATS	340 ^d	-	357	RCT	1.7 ^{b,d}	-	2.3 ^b	-	-	-	-	-	-
Stokes 2018 (15)	2004-13	71-80	cl-IIA	NCDB	5,504 ^g	-	18,084	-	2.5 ^d	-	3.1	-	-	-	-	-	-
Liu 2014 (16)	2004-10	>70	cl-IIA	China x1	45 ^d	-	122	-	0 ^d	-	0	-	-	-	-	-	-
Rostad 2005 (17)	1993-00	≥70	All	Norwegian registry	73 ^d	-	462	-	4 ^d	-	6	-	-	-	-	-	-
Tsutani 2018 (18)	2007-15	≥75	cl-IIA	Japan x1	99 ^d	-	106	Y	0 ^d	-	0.9	-	-	-	5 ^d	-	10
Fiorelli 2016 (19)	2006-12	≥75	cl-IIA	Italy x8	90 ^d	-	149	-	0 ^d	-	0.6	-	-	-	8 ^d	-	11
Kilic 2009 (20)	2002-07	≥75	cl-IIA	US x1, 36% VATS	-	78	106	-	-	1.3	4.7	-	30	50	-	12	26
Dell'Amore 2013 (21)	2000-10	≥75	cl-IIIB	Italy x3	71 ^d	-	218 ^g	Y	2.8 ^d	-	5.5 ^g	-	-	-	-	-	-
Okami 2010 (22)	1990-07	≥75	plA	Japan x1, excluded GGN	54 ^d	-	79	-	-	-	-	28 ^d	-	25	9 ^d	-	5
Stokes 2018 (15)	2004-13	>80	cl-IIA	NCDB	1,875 ^d	-	3,949	-	2.8 ^d	-	4.4	-	-	-	-	-	-
Linden 2014 (23)	2009-11	≥80	cl-IIIA	STS	534	-	534 ^h	Y	1.7	-	2.3 ^h	-	-	-	5	-	8 ^h
Dell'Amore 2015 (24)	2000-10	≥80	cl-IIIB	Italy x3	29 ^d	-	44 ^g	Y	3.4 ^d	-	2.3 ^g	31 ^d	-	48 ^g	-	-	-
Zhang 2012 (25)	1998-11	≥80	pl-IIIA	China x1	20 ^d	-	32	-	-	-	-	25 ^d	-	56	-	-	-
Okami 2009 (26)	1999	≥80	cl-IIA	Japanese registry	122 ^d	-	245	Y	0 ^d	-	2	-	-	-	-	-	-
Dominguez 2006 (27)	1985-04	≥80	All	US x1, historic cohort	78	29	240	Y	10	3.5	5	-	-	-	-	-	-

Inclusion criteria: studies 2000–2021 reporting short-term morbidity and mortality for segment or wedge resections in older cohorts, ≥50 patients total. Red font highlights potential weaknesses, e.g., accrual occurring primarily before 2000.

^a, stage is 8th edition (reported stage is translated into current 8th edition nomenclature for the sake of uniformity and contemporary application); ^b, 90-day; ^c, cardiopulmonary complications (in brackets because not very comparable to any complication); ^d, sublobar, not further defined; ^e, T1-4, N0,1 (no N2 tumors included); 80% were stage I-IIA; ^f, predominantly wedge; ^g, includes lobectomy and bilobectomy; ^h, includes some segmentectomies.

CanCORS, Cancer Care Outcomes Research and Surveillance consortium (US, large multicenter database; GGN, ground glass nodule; Gr, grade; Lobe, lobectomy; MV Adj, multivariate adjustment (for short-term outcomes); NCDB, US national cancer database; RCT, randomized controlled trial; SEER, Surveillance, Epidemiology, and End Results database; Seg, segmentectomy; STS, Society of Thoracic Surgery database; VATS, video-assisted thoracic surgery; W, wedge; Y, yes.